Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Atg4B-IN-2 is a potent and selective Atg4B inhibitor with anticancer activity that inhibits the activity of Atg4B and PLA2.Atg4B-IN-2 resists the anticancer activity of anti-desiccation-resistant prostate cancer drugs through autophagy.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 115.00 | |
5 mg | In stock | $ 228.00 | |
10 mg | In stock | $ 380.00 | |
25 mg | In stock | $ 685.00 | |
50 mg | In stock | $ 998.00 | |
100 mg | In stock | $ 1,500.00 |
Description | Atg4B-IN-2 is a potent and selective Atg4B inhibitor with anticancer activity that inhibits the activity of Atg4B and PLA2.Atg4B-IN-2 resists the anticancer activity of anti-desiccation-resistant prostate cancer drugs through autophagy. |
Targets&IC50 | Atg4B:3.1 μM (Ki), Atg4B:11 μM, PLA2:3.5 μM |
In vitro |
In a dose-dependent manner, Atg4B-IN-2 (compound 21f) (1-10 μM; 2 hours) restores p62 expression in cells treated with amino acid-free (AF) conditions [1]. At concentrations of 1 and 5 μM (2 hours), Atg4B-IN-2 moderately decreases autophagic vesicles at 1 μM and almost completely inhibits autophagy at 5 μM [1]. At a concentration of 5 μM (2 hours), Atg4B-IN-2 inhibits Abi-induced autophagy, significantly enhances apoptotic cell death, and increases sensitivity to Abi [1]. |
Molecular Weight | 330.46 |
Formula | C21H30O3 |
CAS No. | 2765008-88-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 80 mg/mL (242.09 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Atg4B-IN-2 2765008-88-4 Autophagy Metabolism Phospholipase inhibitor inhibit